More dose was not better in definitive ESCC. Three-year PFS: 45% with 50.4 Gy vs 26% with 60 Gy (phase 2, n=97), but the difference vanished after covariate adjustment. Single-center trial using S-1/nedaplatin. No support for escalation.
pubmed.ncbi.nlm.nih.gov/42537853/
pubmed.ncbi.nlm.nih.gov/42537853/